CollPlant Biotechnologies has announced the completion of a nonclinical program supporting the development of its photocurable dermal filler, which combines hyaluronic acid with a modified form of recombinant human collagen (rhCollagen). The company plans to advance the product candidate into clinical trials.
The injectable filler is administered as a viscoelastic gel that can be sculpted and then stabilized using a proprietary light-based curing device. Upon light activation, the gel forms a semisolid implant designed to maintain its shape under mechanical stress. According to CollPlant, this dual-phase design allows for both immediate contouring and long-term tissue integration.
“The successful completion of our extensive nonclinical program marks an important milestone for CollPlant, allowing us to enter clinical development of our photocurable regenerative filler,” said Yehiel Tal, Chief Executive Officer of CollPlant. “By harnessing the unique properties of our rhCollagen technology, we aim to redefine the standard of care in aesthetic medicine with a novel solution that not only delivers immediate contouring and support but also promotes natural tissue integration for long-lasting results. We are excited to advance this product candidate another step toward the clinic and closer to providing physicians and patients with a next-generation alternative.”
The preclinical evaluation included a 1-year in vivo study that demonstrated long-term durability, along with biocompatibility assessments meeting international standards. The combined results established a strong foundation for clinical advancement, and CollPlant is now scaling and optimizing its manufacturing process to ensure readiness for the upcoming clinical trial.
